Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Neurooncol. 2012 May;108(1):11-27. doi: 10.1007/s11060-011-0793-0. Epub 2012 Jan 20.

Recent advances in the molecular understanding of glioblastoma.

Author information

  • 1Department of Neurosurgery, H2 247, Neurosurgical Center Amsterdam, Location AMC, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. f.e.bleeker@amc.uva.nl

Abstract

Glioblastoma is the most common and most aggressive primary brain tumor. Despite maximum treatment, patients only have a median survival time of 15 months, because of the tumor's resistance to current therapeutic approaches. Thus far, methylation of the O (6)-methylguanine-DNA methyltransferase (MGMT) promoter has been the only confirmed molecular predictive factor in glioblastoma. Novel "genome-wide" techniques have identified additional important molecular alterations as mutations in isocitrate dehydrogenase 1 (IDH1) and its prognostic importance. This review summarizes findings and techniques of genetic, epigenetic, transcriptional, and proteomic studies of glioblastoma. It provides the clinician with an up-to-date overview of current identified molecular alterations that should ultimately lead to new therapeutic targets and more individualized treatment approaches in glioblastoma.

PMID:
22270850
[PubMed - indexed for MEDLINE]
PMCID:
PMC3337398
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Write to the Help Desk